Latest studies
- RecruitingPHASE2
A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis
This study looks at a medicine called Etrasimod for children aged 2-11 with a gut condition called ulcerative colitis. It aims to see if the medicine is safe, works well, and how the body handles it. Some children might continue taking it for a longer time.
Colitis, UlcerativePoland - Not yet recruitingPHASE3
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
This study is looking at a new medicine, AZD6234, for adults with Type 2 diabetes who are also overweight or have obesity. It aims to see how well it helps with weight loss and how safe it is compared to a dummy medicine.
Obesity or OverweightDiabetes Mellitus, Type 2Poland - Recruiting
A Non-interventional Study of Participants With BPDCN Treated With Chemotherapy
This study looks at how chemotherapy treatments work for adults in the UK with a rare blood cancer called BPDCN. It aims to understand how safe and effective these treatments are in real-world settings, helping doctors compare them with new drug studies.
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)Poland - RecruitingPHASE3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
This study looks at the long-term safety and effectiveness of a cancer drug called pembrolizumab (and related treatments) for people with advanced cancers. It's for patients who are already receiving these treatments in other studies and want to continue.
Solid TumorsHematologic MalignanciesPoland - RecruitingPHASE3
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
This study is testing a new drug, neladalkib, for people with a common type of lung cancer (NSCLC) that's ALK-positive. It's comparing neladalkib to a standard treatment, alectinib, to see if neladalkib works better at stopping the cancer from growing.
Non-small Cell Lung CancerAnaplastic Lymphoma Kinase-positivePoland - RecruitingPHASE2
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
This study is testing a new medicine, IMVT-1402, for adults with Graves' disease whose thyroid is still overactive despite current treatment. We want to see if it works, is safe, and is well-tolerated. It's a Phase 2 trial. You can find out more if you're interested.
Graves' DiseasePoland - RecruitingPHASE3
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
This study is testing a new medicine, Pasritamig, for men with advanced prostate cancer that has spread and is no longer responding to hormone treatments. We want to see if Pasritamig helps men live longer compared to a dummy medicine, alongside their usual supportive care.
Metastatic Castration-resistant Prostatic NeoplasmsPoland - RecruitingPHASE3
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
This study is looking into whether a medicine called baricitinib can delay Type 1 Diabetes in children and adults who are at a high risk of developing it. It's a key step in preventing the condition.
Diabetes Mellitus, Type 1Poland - RecruitingPHASE2, PHASE3
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
This study is for people with a type of lung cancer that has a specific gene change (EGFR mutation) and has not responded to previous treatment. It compares a new medicine called Iza-bren with standard chemotherapy (carboplatin or cisplatin plus pemetrexed) to see which works better.
Non-Small Cell Lung CancerPoland - RecruitingPHASE3
A Study of Pitolisant in Patients With Prader-Willi Syndrome
This study is testing a medication called Pitolisant for people aged 6 and over with Prader-Willi syndrome. It aims to see if it helps with excessive sleepiness and other behaviors, compared to a dummy pill.
Prader-Willi SyndromePoland - Active not recruitingPHASE3
Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL
This study tested new treatments for Chronic Lymphocytic Leukemia (CLL), a type of blood cancer, in people who had not been treated before. It compared different drug combinations to see which worked best to slow down or stop the cancer's progress.
Chronic Lymphocytic LeukemiaPoland - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
This study is looking at a new combination of treatments, Inavolisib and Phesgo, for HER2-positive breast cancer that has spread. We want to see if this new combination works better and is safe compared to Phesgo alone after initial treatment.
Metastatic Breast CancerPoland - Active not recruitingPHASE2
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
This study looks at a drug called entrectinib for different types of advanced cancer. It focuses on cancers with specific genetic changes (NTRK, ROS1, or ALK gene fusions). Researchers want to see if entrectinib can help treat these cancers.
Breast CancerCholangiocarcinomaColorectal CancerHead and Neck NeoplasmsPoland - RecruitingPHASE2, PHASE3
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
This study looks at a new drug called adagrasib, on its own and with another drug, pembrolizumab, for people with advanced lung cancer. It's for those with a specific gene change (KRAS G12C) who haven't had treatment yet.
Advanced Non-Small Cell Lung CancerMetastatic Non-Small Cell Lung CancerPoland - RecruitingPHASE2
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
This study is looking into a new medication called Afimkibart for adults with moderate to severe rheumatoid arthritis. It's for those who haven't found enough relief from or can't take other common treatments. The aim is to see how well it works and if it's safe.
Rheumatoid ArthritisPoland - Active not recruitingPHASE1
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors
This study is testing a new drug called dostarlimab for people with advanced cancers that haven't responded to other treatments. It aims to find the safest and most effective dose, and see how well it works against different types of advanced solid tumours.
NeoplasmsPoland - RecruitingPHASE2
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
This study is looking for adults with Graves' disease whose thyroid is overactive despite medication. It aims to see if a new medicine, IMVT-1402, is safe and helps control their thyroid better than a dummy medicine. We want to find a better treatment.
Graves' DiseasePoland - RecruitingPHASE2, PHASE3
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
This study looks at a new drug, Navlimetostat, combined with standard treatments for advanced lung cancer. It compares this combination to standard treatments alone in patients whose cancer has a specific genetic change called an MTAP deletion. The aim is to see if the new combination works better.
Metastatic Non-small Cell Lung Cancer With MTAP DeletionPoland - RecruitingNA
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
This study looks at whether a special feature in a Medtronic pacemaker can help lower high blood pressure. It compares having this feature on versus off in people who either need a pacemaker or already have one and also have high blood pressure.
HypertensionHypertension, SystolicHypertension, EssentialPoland - RecruitingPHASE3
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
This study is looking into new treatments, pozelimab and cemdisiran, for Geographic Atrophy (GA), an advanced form of Age-related Macular Degeneration (AMD). It compares these new drugs, alone or together, against a placebo to see if they can slow down vision loss.
Age-related Macular Degeneration (AMD)Geographic Atrophy (GA)Poland - RecruitingPHASE3
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS
This study is testing a drug called pridopidine for people with Amyotrophic Lateral Sclerosis (ALS), also known as Motor Neurone Disease. We want to see if pridopidine can slow down how ALS progresses and if it's safe to use. Participants will take the drug or a dummy pill daily.
Amyotrophic Lateral SclerosisPoland - RecruitingPHASE3
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
This study is looking into a new medication called Elecoglipron for weight management. It's for adults who are overweight or have obesity, with or without Type 2 diabetes, to see if it helps them lose weight safely when combined with diet and exercise.
Weight ManagementPoland - RecruitingPHASE1
An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis
This study is looking at how a new medicine, Afimkibart, affects how your body processes other common medicines in people with active ulcerative colitis. We want to see if it changes how your body uses them.
Active Ulcerative ColitisPoland - RecruitingPHASE3
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
This study, called LUNAR-2, is looking at a new treatment for advanced lung cancer. It combines a device called NovoTTF-200T with standard immunotherapy (pembrolizumab) and chemotherapy to see if it helps people live longer and stops cancer from growing.
Metastatic Non-small Cell Lung CancerPoland - RecruitingPHASE2
Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis
This study is looking into a new treatment called ABBV-142 for a lung condition called Idiopathic Pulmonary Fibrosis (IPF). It aims to check if the new drug is safe, what side effects it might cause, and if it helps improve the condition compared to a dummy drug.
Idiopathic Pulmonary FibrosisPoland - Active not recruitingPHASE3
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
This study is looking at a new drug, epcoritamab, combined with standard treatments for follicular lymphoma, a type of blood cancer. We want to see if this combination is safe and effective in people who haven't been treated for this condition before.
Follicular Lymphoma (FL)Poland - RecruitingPHASE2
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children
This study is looking at a medicine called eluxadoline to see if it can help children aged 6-17 with Irritable Bowel Syndrome (IBS) that causes diarrhoea. Researchers want to understand how it works in children, if it's safe, and how well it helps manage symptoms.
Irritable Bowel SyndromePoland - RecruitingPHASE2
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
This study looks at new treatments for advanced stomach or oesophageal cancer with a specific protein called HER2. We're testing a new drug, trastuzumab deruxtecan, by itself or with other common cancer medicines to see if it's safe and effective.
Gastric CancerPoland - Active not recruitingPHASE3
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
This study is for people with ovarian or breast cancer who are already receiving olaparib in a different study and are still benefiting. It allows them to continue getting their treatment if their current study ends, ensuring they keep receiving a medication that is helping them.
Ovarian CancerBreast CancerPoland - RecruitingPHASE3
Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy
This study is testing a new medicine, Givinostat, for boys aged 9-17 with Duchenne muscular dystrophy who use a wheelchair. Researchers want to see if it helps reduce muscle decline and is safe to use. Half the boys will get the medicine, and half a dummy pill for 18 months.
Duchenne Muscular DystrophyPoland - Active not recruitingPHASE3
A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer
This study looks at new ways to treat advanced or returning womb cancer. It compares a drug called dostarlimab, with or without another drug called niraparib, alongside standard chemotherapy, against chemotherapy plus a dummy drug, to see if these new treatments work better and are safe.
NeoplasmsPoland - RecruitingPHASE3
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
This study is testing a new medicine, depemokimab, for people with moderate to severe COPD that involves a specific type of inflammation. We want to see if starting this medicine early helps improve their breathing and reduce flare-ups.
Pulmonary Disease, Chronic ObstructivePoland - Active not recruitingPHASE3
Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
This study looked at new ways to treat a type of lung cancer called extensive-stage small cell lung cancer (ES-SCLC). It compared a combination of medicines with standard chemotherapy to see if it could help people live longer. The study was changed partway through, so the focus shifted.
Small Cell Lung CarcinomaPoland - Active not recruitingPHASE2, PHASE3
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
This study is looking at a new medicine called guselkumab for people with ulcerative colitis that isn't well-controlled. We want to see if it helps reduce symptoms and if it's safe to use for those with moderate to severe forms of the condition.
Ulcerative ColitisPoland - Active not recruitingPHASE3
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
This study looks at a new drug, tafasitamab, alongside standard treatments for follicular lymphoma and marginal zone lymphoma that have come back or not responded well. It aims to see if adding this new drug works better than the usual treatment alone.
Follicular LymphomaMarginal Zone LymphomaPoland - RecruitingPHASE3
An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED
This study is looking into a new eye drop called cenegermin to treat a persistent sore on the front of the eye (cornea). Researchers want to see if it helps the sore heal better and if it's safe compared to a dummy treatment. It involves different treatment and follow-up periods.
Persistent Corneal Epithelial DefectPoland - Active not recruitingPHASE3
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
This study is looking at a new drug, quizartinib, combined with standard chemotherapy for adults recently diagnosed with a specific type of leukaemia called AML. We want to see if this combination improves treatment outcomes compared to chemotherapy alone.
LeukemiaPoland - Active not recruitingPHASE3
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).
This study looks at new treatments for ovarian cancer that has come back and is resistant to platinum-based chemotherapy. It combines existing drugs like paclitaxel and bevacizumab with a new drug called pembrolizumab, hoping to stop the cancer from growing for longer.
Ovarian CancerCarcinoma, Ovarian EpithelialFallopian Tube NeoplasmsPoland - RecruitingPHASE4
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy
This study looks at a medicine called risdiplam for young children (under 2) with a muscle condition called spinal muscular atrophy (SMA). It's for those who had gene therapy but aren't getting better or are getting worse. The study checks if risdiplam is safe and helps them.
Muscular Atrophy, SpinalPoland - Active not recruitingPHASE3
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors
This study compares a new medicine, crovalimab, to an existing one, eculizumab, for people with a rare blood condition called PNH. It's looking at how safe and effective crovalimab is in patients already receiving similar treatments.
Paroxysmal Nocturnal HemoglobinuriaPoland - Active not recruitingPHASE3
A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)
This study looks at a new drug called benralizumab for Hypereosinophilic Syndrome (HES) in people aged 12 and over. It compares benralizumab to a dummy drug to see if it's safe and helps reduce HES symptoms.
Hypereosinophilic SyndromePoland - RecruitingPHASE3
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
This study is testing a new medicine, cladribine, in pill form for people with a muscle weakening condition called myasthenia gravis. We want to see if it helps and if it's safe compared to a dummy pill. We're also looking at its long-term effects and how the body uses the medicine.
Generalized Myasthenia GravisPoland - RecruitingPHASE3
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
This study is for people who have already taken part in other studies for a medicine called sotatercept, used to treat Pulmonary Arterial Hypertension (PAH). It aims to check the long-term safety and how well people tolerate sotatercept when taken with their usual PAH treatments.
Pulmonary Arterial HypertensionPoland - RecruitingPHASE3
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
This study looks at a new medicine, NNC0487-0111, for people with heart failure and obesity. It compares the medicine to a dummy treatment (placebo) to see if it's safe and helps improve heart health.
ObesityHeart FailurePoland - Active not recruitingPHASE3
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)
This study is looking at a new medicine called baricitinib for children aged 1 to 17 with a type of arthritis called systemic juvenile idiopathic arthritis (sJIA). It aims to see if baricitinib is safe and helps to reduce their symptoms.
Systemic Juvenile Idiopathic ArthritisPoland - Active not recruitingPHASE3
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
This study compares a new medication, Bomedemstat, with a standard treatment, Hydroxyurea, for people with Essential Thrombocythemia (ET). It wants to see if Bomedemstat works better at controlling ET for those new to treatment.
Essential ThrombocythemiaPoland - Active not recruitingPHASE3
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
This study is testing a new medicine, tulisokibart, for people with moderate to severe ulcerative colitis. It aims to see if the medicine can help people feel better and stay in remission, compared to a dummy medicine, both in the short and long term.
Ulcerative ColitisPoland - Active not recruitingPHASE3
Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer
This study is testing a new combination treatment for a type of bladder cancer that hasn't spread deep into the bladder wall. It's comparing a new drug called Durvalumab with the standard treatment to see if it's more effective and safe.
Non-muscle-invasive Bladder CancerPoland - RecruitingPHASE1
A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A
This study is looking at a new medicine called Inno8 for people with haemophilia A. Its main goal is to check how different amounts of the medicine work and if it's safe. It's a short study lasting about 11 weeks.
Haemophilia APoland - Active not recruitingPHASE3
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
This study is comparing two treatments, belzutifan plus pembrolizumab, against pembrolizumab alone, for kidney cancer that has been removed. It aims to see if the combination treatment can prevent the cancer from returning.
Carcinoma, Renal CellPoland